Results 231 to 240 of about 931,067 (298)

Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development. [PDF]

Front Toxicol
Nicholas T, Morinello E, Moudgal C, Beaulieu A, Graham J.   +4 more
europepmc   +1 more source

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

Advanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena, Marcelino Telechea, Daniel Fernández, Alba García‐Martín, Ángeles Canales, Silvia Ortega‐Gutiérrez   +5 more
wiley   +1 more source

Disproportionality Analysis of Fluoroquinolone-Associated Peripheral Neuropathy in the FAERS Database (2007-2024). [PDF]

Clin Transl Sci
Shamim N, Doughty K, Chau HT, Brown J, Baldock R, Au NPB.   +5 more
europepmc   +1 more source

Carboranyl‐Curcuminoids for the Neutron Capture‐Based Treatment of Amyloid Aggregates in Alzheimer's Disease

Advanced Science, EarlyView.
The 10B‐enriched monocarbonyl analog of curcumin (BMAC) 10B‐9 enables site‐specific Boron Neutron Capture Therapy (BNCT) on amyloid‐β (Aβ) fibrils. Neutron irradiation induces histidine oxidation and fibril destabilization, as revealed by 1H‐NMR and FESEM analyses.
Sebastiano Micocci, Stefano Parisotto, Diego Alberti, Alberto Lanfranco, Valeria Bitonto, Polyssena Renzi, Martina Salmi, Andrea Magnani, Federica Dal Bello, Katiuscia Pagano, Laura Ragona, Nicoletta Protti, Annamaria Deagostino, Simonetta Geninatti Crich   +13 more
wiley   +1 more source

Priority without progress: the FDA's neglected tropical disease voucher program after 18 years. [PDF]

Health Aff Sch
Goh M, Outterson K, Kesselheim AS.
europepmc   +1 more source

Artesunate Ameliorates APAP‐induced Liver Injury by Promoting NEDD4L‐Mediated Ubiquitination and Degradation of TXNIP

Advanced Science, EarlyView.
ABSTRACT Liver injury can lead to severe acute liver failure and even death in patients. Artesunate (ART), which is a derivative of artemisinin that has been approved by the FDA for the treatment of malaria, has significant regulatory effects on cell death and inflammation.
Zhe Zhang, Hongyi Zhang, Haixiang Guo, Xiwen Zhang, Yidan Wang, Baoyin Wang, Tong Wang, Guokun Zhao, Qing Zhang, Fei Gao, Shuang Liang, Hao Jiang, Yu Ding, Xiliang Du, Jiabao Zhang, Yi Zheng, Xinwei Li, Bao Yuan   +17 more
wiley   +1 more source

Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]

Front Oncol
Madar IH, Kammarambath SR.
europepmc   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

Federating AI-related regulations for human therapeutics: an AI-enabled, continuously updating regulatory intelligence system. [PDF]

Front Drug Saf Regul
Singh R, Pareek M, Prokle M, Sanchez E, Hohgrawe U, Auclair JR.   +5 more
europepmc   +1 more source

Regulatory, ethical, and clinical barriers to exosome use in interventional pain medicine. [PDF]

Interv Pain Med
Bourcier AJ, Kirkor ZM.
europepmc   +1 more source